News

Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study

06.25.20

ST. PAUL, MN, June 25, 2020 – Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ:OSUR), and Alimentiv Inc. (formerly Robarts Clinical Trials) today announced they have signed a collaboration agreement for a research study on patients with Acute Severe Ulcerative Colitis (ASUC). The study, titled: “Pharmacokinetics of Infliximab

04.03.20

In this article we’re sharing results from the validation study scientists at Diversigen and DNA Genotek undertook to ensure Diversigen’s viral metagenomics capabilities could be leveraged to help during the COVID-19 pandemic. When I was a boy and I would see scary things in the news, my mother would

05.22.20

PAUL, MN and OAKLAND, CA, May 22, 2020 – Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ:OSUR), and Nom NomTM, a direct-to-consumer pet health brand, today announced that Nom Nom has selected Diversigen as their preferred provider for metagenomics and microbiome sequencing and analysis services. Diversigen will also

05.11.20

OraSure Technologies, Inc. announces that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled scientific bench strength, state-of-the-art laboratory, ability to translate data to insights and collective focus on quality and service. Investor Contact: Roberto Cuca Chief

01.07.20

Acquisition extends OraSure’s leadership position in the microbiome services industry BETHLEHEM, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, today announced that it has entered into a definitive agreement to acquire the outstanding equity of

12.17.19

CARLSBAD, Calif., Dec. 17, 2019 — Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., and CoreBiome, a wholly owned subsidiary of OraSure Technologies, Inc., announced today a collaboration to develop a new test called LifeKit® Prevent, which may represent a microbiome-driven paradigm shift in colon cancer screening. According to the American Cancer

10.21.19

Resistome profiling poses several advantages over PCR or qPCR alone. No prior knowledge of the ARGs of interest is needed in resistome profiling as all the sequences are being compared to curated and updated reference databases. This comparison enables the simultaneous and global characterization of the potential ARGs present

07.31.19

“The virome is comprised of endogenous retroviruses, eukaryotic viruses, and bacteriophages and is increasingly being recognized as an essential part of the human microbiome. The human virome is associated with Type-1 diabetes (T1D), Type-2 diabetes (T2D), Inflammatory Bowel Disease (IBD), Human Immunodeficiency Virus (HIV) infection, and cancer. Increasing evidence

07.31.19

“Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, affect several million individuals worldwide. Crohn’s disease and ulcerative colitis are complex diseases that are heterogeneous at the clinical, immunological, molecular, genetic, and microbial levels.” Read More

04.25.19

Today, CoreBiome announced that leading microbiome researcher Rob Knight, Professor and Director of the Center for Microbiome Innovation at the University of California San Diego, will be joining its scientific advisory board. As an investigator on the National Institutes of Health Human Microbiome Project and a co-founder of the

Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study

Validation of our viral metagenomics sequencing and analysis pipeline for SARS-CoV-2 detection

Diversigen Inc. Selected by Nom NomTM as the Preferred Provider for Metagenomics and Microbiome Sequencing and Analysis Services

OraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries

OraSure Technologies, Inc. Announces Purchase of Diversigen

Prescient Metabiomics and CoreBiome collaborating to develop breakthrough colon cancer screening test

New White Paper on Resistome Profiling

Diversigen bioinformatics team publishes review on the human virome and disease

“Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases”

CoreBiome adds leading microbiome researcher Rob Knight as Scientific Advisor